$49.39+66.41% · 3M
Moving avg
1W+5.17%
1M+24.10%
3M+71.61%
6M+145.72%
YTD+117.48%
1Y+145.97%
3Y+118.15%
5Y+230.81%
52-week range
$15.86100% of range$48.19
Company health
Value0/6
Growth3/6
Profitability2/6
Health4/6
Dividend0/6
Bull vs bear
Strengths
- Analyst consensus is "Buy"
- High return on equity (8178%)
- Revenue compounding 23% a year
Risks
- Currently unprofitable
- Burning free cash flow
- More volatile than the market (beta 1.6)
Key statistics
Valuation
Market cap
$2.41B
Enterprise value
$2.40B
P/E ratio (TTM)
-23.72x
P/S ratio (TTM)
12.12x
EV/EBITDA
-34.01x
Per share & returns
EPS (TTM)
-$1.94
Dividend yield
0.00%
Beta (1Y)
1.57
30-day change
+24.10%
Trading
Volume (24h)
343.66K
Previous close
$49.00
Shares outstanding
48.72M
About UroGen Pharma Ltd.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Symbol
URGN
UroGen Pharma Ltd. is a mid-cap healthcare company in the Biotechnology industry. Its shares are listed on NASDAQ (United States) and trade under the ticker URGN.
Frequently asked questions
What is UroGen Pharma Ltd.'s market cap?
UroGen Pharma Ltd. (URGN) has a market capitalization of $2.41B.
What sector is UroGen Pharma Ltd. in?
UroGen Pharma Ltd. operates in the Healthcare sector, Biotechnology industry.
What exchange does URGN trade on?
URGN trades on NASDAQ.
Appears in
Eli Lilly and CompanyLLY
$1,218.39-0.15%
$1.15T cap
Johnson & JohnsonJNJ
$261.39+0.20%
$629.92B cap
AbbVie Inc.ABBV
$250.32+0.63%
$442.26B cap
UnitedHealth Group IncorporatedUNH
$402.17-0.84%
$365.22B cap
Roche Holding AGSWX: ROP
CHF 362.30-0.88%
$355.30B cap
Merck & Co., Inc.MRK
$134.77+1.39%
$332.86B cap
Novartis AGSWX: NOVN
CHF 123.74-0.37%
$289.76B cap
AstraZeneca PLCLON: AZN
£117.08+0.05%
$245.27B cap